More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study

Trials

Methodology

Honghao Li¹  Paul Trichelair¹  Félix Balazard¹  Raphaëlle Momal¹  Michael G. B. Blum¹ 

[1] Owkin Inc, New York, USA;

关键词: Covariate adjustment;    Trial design;    Cox regression;    Eligibility criteria;   

DOI  :  10.1186/s13063-023-07375-0

 received in 2023-02-07, accepted in 2023-05-12,  发布年份 2023

来源: Springer

【 摘 要 】

Adjustment for prognostic covariates increases the statistical power of randomized trials. The factors influencing the increase of power are well-known for trials with continuous outcomes. Here, we study which factors influence power and sample size requirements in time-to-event trials. We consider both parametric simulations and simulations derived from the Cancer Genome Atlas (TCGA) cohort of hepatocellular carcinoma (HCC) patients to assess how sample size requirements are reduced with covariate adjustment. Simulations demonstrate that the benefit of covariate adjustment increases with the prognostic performance of the adjustment covariate (C-index) and with the cumulative incidence of the event in the trial. For a covariate that has an intermediate prognostic performance (C-index=0.65), the reduction of sample size varies from 3.1% when cumulative incidence is of 10% to 29.1% when the cumulative incidence is of 90%. Broadening eligibility criteria usually reduces statistical power while our simulations show that it can be maintained with adequate covariate adjustment. In a simulation of adjuvant trials in HCC, we find that the number of patients screened for eligibility can be divided by 2.4 when broadening eligibility criteria. Last, we find that the Cox-Snell RCS2\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$${R}_{\mathsf{C}\mathsf{S}}^{2}$$\end{document} is a conservative estimation of the reduction in sample size requirements provided by covariate adjustment. Overall, more systematic adjustment for prognostic covariates leads to more efficient and inclusive clinical trials especially when cumulative incidence is large as in metastatic and advanced cancers. Code and results are available at https://github.com/owkin/CovadjustSim.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_252_Article_IEq37.gif

40517_2023_252_Article_IEq35.gif

Fig. 2

40517_2023_252_Article_IEq33.gif

Fig. 1

40517_2023_252_Article_IEq31.gif

40517_2023_252_Article_IEq30.gif

40517_2023_252_Article_IEq29.gif

Fig. 3

40517_2023_252_Article_IEq26.gif

Fig. 3

Fig. 4

Fig. 19

Fig. 18

Fig. 12

Fig. 2

Fig. 4

Fig. 2

Fig. 16

Fig. 1

Fig. 14

Fig. 3

Fig. 13

Fig. 12

Fig. 1

Fig. 11

42004_2023_911_Article_IEq62.gif

Fig. 10

42004_2023_911_Article_IEq60.gif

Fig. 9

Fig. 7

Fig. 7

Fig. 6

Fig. 2

Fig. 9

Fig. 1

Fig. 1

42004_2023_911_Article_IEq48.gif

Fig. 5

Fig. 4

Fig. 3

Fig. 2

Fig. 2

Fig. 1

Fig. 5

42004_2023_911_Article_IEq37.gif

42004_2023_911_Article_IEq45.gif

Fig. 1

42004_2023_911_Article_IEq042.gif

42004_2023_911_Article_IEq041.gif

Fig. 1

42004_2023_911_Article_IEq36.gif

Fig. 6

42004_2023_911_Article_IEq33.gif

42004_2023_911_Article_IEq32.gif

Fig. 2

Fig. 1

Fig. 5

42004_2023_911_Article_IEq031.gif

42004_2023_911_Article_IEq30.gif

Fig. 5

42004_2023_911_Article_IEq28.gif

Fig. 8

Fig. 1

42004_2023_911_Article_IEq25.gif

Fig. 4

42004_2023_911_Article_IEq23.gif

Fig. 3

42004_2023_911_Article_IEq20.gif

42004_2023_911_Article_IEq19.gif

42004_2023_911_Article_IEq18.gif

42004_2023_911_Article_IEq17.gif

42004_2023_911_Article_IEq16.gif

42004_2023_911_Article_IEq15.gif

Fig. 3

42004_2023_911_Article_IEq13.gif

42004_2023_911_Article_IEq12.gif

42004_2023_911_Article_IEq10.gif

42004_2023_911_Article_IEq9.gif

42004_2023_911_Article_IEq8.gif

Fig. 7

Fig. 2

Fig. 1

40854_2023_495_Article_IEq32.gif

Fig. 9

12302_2023_750_Article_IEq9.gif

12302_2023_750_Article_IEq8.gif

Fig. 4

Fig. 6

Fig. 8

Fig. 2

40854_2023_495_Article_IEq22.gif

Fig. 1

Fig. 10

42004_2023_932_Article_IEq5.gif

Fig. 3

Fig. 3